Archil Jaliashvili: How Next-Generation Oxygen Carriers Build Healthcare Resilience
Archil Jaliashvili, Co-owner, General Manager of SkinAI, Co-Chief Executive Officer at GeoBio Pharm, shared a post on LinkedIn about a recent article by Zhen W Mei et al., published in American Journal of Therapeutics, adding:
“We are facing a national blood crisis, with summer blood donations falling to a four-year low.
Your help is needed now to avoid surgery delays, postponed cancer treatments and strained emergency care.”
American Red Cross
We have had an answer for this challenge for more than 25 years.
HBOC-201 (Hemopure) had an established FDA Expanded Access pathway, including emergency single-patient IND use, for life-threatening situations when blood was unavailable or transfusion was not an option.
The lesson is important: this was never technology and product problem.
It was also a mindset and system-design challenge.
Today, we continue advancing this platform with next-generation technology: a new BHOC biosimilar approach, supported by advanced SUT manufacturing, AI-enabled control systems, modular production and improved purification technologies.
BHOC is not a blood substitute.
It is an oxygen carrier designed as a bridge – a universal, immediately available solution to support patients when donor blood is delayed, unavailable or insufficient.
Combined with emerging logistics solutions such as drone delivery, or to have it in every EMS, we can rethink how critical oxygen support reaches patients and hospitals.
The goal is simple:
No patient should lose access to lifesaving treatment because compatible donor blood is not available.
The future of transfusion medicine is not only about increasing supply.
It is about creating resilience.
Create sovereign healthcare capabilities.
Clinical Trials.gov
- ID NCT02684474
- ID NCT01881503
- ID NCT03633604
For more information, to join this effort, advocate for change, or explore collaboration opportunities, please contact us.
Let’s work together to save lives and build a more resilient healthcare system.
The next blood crisis should not become another preventable tragedy.
We are not here to replace existing solutions – we are here to support, collaborate, and provide additional tools when patients need them most.
Together, we can create a future where no patient is left without critical oxygen support because donor blood is unavailable.”
Title: Artificial Oxygen Carriers Save Lives in Expanded Access Use: Three Cases when Blood Was Not an Option
Authors: Zhen W. Mei, Jay S. Raval, Justin Arnall, Sophia H. Hwang, Karen Rodberg, Doris Quon, Dawn C. Ward, Alyssa Ziman, Andrea M. McGonigle, Jonathan S. Jahr
Stay updated with Hemostasis Today.
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS
-
Aug 9, 2026, 08:39Alejandro González Veliz: The Future of Cardiogenic Shock Lies in Precision Medicine
-
Aug 9, 2026, 08:29Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
-
Aug 9, 2026, 08:18Fawaz AlOtaibi: Why Experts Are Challenging the New Stroke Guideline
-
Aug 9, 2026, 08:08Jason Carney: Addressing the National Blood Shortage Through AI-Driven Patient Blood Management
-
Aug 9, 2026, 07:54Hamdy Alkady: FDA Approves the First Oral PCSK9 Inhibitor
-
Aug 9, 2026, 07:51Mostafa Hammam: Antibody Panels in Blood Bank Feeling Like a Chaotic Puzzle? Here is How to Master the Grid
-
Aug 9, 2026, 07:32Heghine Khachatryan: Less Frequent INR Monitoring – Does It Necessarily Mean Poorer Anticoagulation Control?
-
Aug 9, 2026, 07:13Victorien Monguillon: The Hidden Burden of Non-Major Extracranial Bleeding in Oral Anticoagulant Therapy